News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,306 Results
Type
Article (43589)
Company Profile (315)
Press Release (675402)
Section
Business (211673)
Career Advice (2091)
Deals (36373)
Drug Delivery (94)
Drug Development (82159)
Employer Resources (173)
FDA (16674)
Job Trends (15284)
News (355747)
Policy (33341)
Tag
Academia (2683)
Alliances (52311)
Alzheimer's disease (1321)
Approvals (16640)
Artificial intelligence (202)
Bankruptcy (359)
Best Places to Work (11914)
Biotechnology (222)
Breast cancer (218)
Cancer (1614)
Cardiovascular disease (123)
Career advice (1747)
CAR-T (119)
Cell therapy (338)
Clinical research (65832)
Collaboration (634)
Compensation (317)
COVID-19 (2641)
C-suite (147)
Data (1533)
Diabetes (196)
Diagnostics (6500)
Earnings (86738)
Employer resources (151)
Events (115202)
Executive appointments (536)
FDA (17508)
Funding (569)
Gene therapy (237)
GLP-1 (653)
Government (4450)
Healthcare (19460)
Infectious disease (2741)
Inflammatory bowel disease (117)
Interviews (320)
IPO (16763)
Job creations (3815)
Job search strategy (1490)
Layoffs (443)
Legal (8096)
Lung cancer (237)
Manufacturing (227)
Medical device (13975)
Medtech (13980)
Mergers & acquisitions (19926)
Metabolic disorders (523)
Neuroscience (1704)
NextGen: Class of 2025 (6839)
Non-profit (4611)
Northern California (1947)
Obesity (296)
Opinion (200)
Patents (144)
People (58929)
Phase I (20649)
Phase II (28970)
Phase III (21498)
Pipeline (642)
Postmarket research (2581)
Preclinical (8814)
Radiopharmaceuticals (258)
Rare diseases (305)
Real estate (6222)
Regulatory (22407)
Research institute (2450)
Resumes & cover letters (361)
Southern California (1694)
Startups (3832)
United States (17669)
Vaccines (619)
Weight loss (206)
Date
Last 7 days (635)
Last 30 days (2651)
Last 365 days (35590)
2025 (2727)
2024 (36221)
2023 (41136)
2022 (52397)
2021 (56994)
2020 (55615)
2019 (48410)
2018 (36442)
2017 (33541)
2016 (33139)
2015 (39358)
2014 (32941)
2013 (27985)
2012 (30242)
2011 (30847)
2010 (28809)
Location
Africa (754)
Arizona (215)
Asia (40094)
Australia (6669)
California (4490)
Canada (1614)
China (378)
Colorado (204)
Connecticut (218)
Europe (87570)
Florida (639)
Georgia (163)
Illinois (454)
Indiana (255)
Maryland (709)
Massachusetts (3497)
Michigan (206)
Minnesota (330)
New Jersey (1266)
New York (1284)
North Carolina (842)
Northern California (1947)
Ohio (164)
Pennsylvania (1040)
South America (1151)
Southern California (1694)
Texas (656)
Utah (133)
Washington State (448)
719,306 Results for "theralase technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Theralase(R) Technology Effective in Virus Inactivation
Theralase Technologies Inc. is pleased to announce that it’s lead compound, Ruvidar TM, has been proven effective in the inactivation of various viruses.
June 4, 2024
·
7 min read
Press Releases
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
January 27, 2025
·
7 min read
Business
Theralase(R) Release’s 1Q2024 Financial Statements
Theralase Technologies Inc. has released the Company’s unaudited interim consolidated 1Q2024 financial statements.
May 30, 2024
·
14 min read
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
Theralase® Technologies Inc. is providing a reminder notice for its Annual General and Special Meeting for shareholders of Theralase® that is scheduled for Wednesday, June 19th at 4:30 pm ET at its corporate head office; specifically, 41 Hollinger Road, Toronto, Ontario, M4B 3G4.
June 14, 2024
·
4 min read
Press Releases
Theralase(R) Launches New Clinical Study Site in Canada
December 6, 2024
·
9 min read
Press Releases
Theralase(R) Launches Three New Clinical Study Sites in USA
December 9, 2024
·
11 min read
Theralase(R) Successfully Destroys Lung Cancer
Theralase Technologies Inc. is pleased to announce that it’s lead compound, Ruvidar TM , combined with transferrin to form the compound RuvidarTM, combined with transferrin to form the compound Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”).
June 6, 2024
·
7 min read
Business
Theralase(R) Expands Clinical Team - May 02, 2024
Theralase® Technologies Inc. is pleased to announce that it has expanded its clinical team with the hiring of two Clinical Research Associates.
May 2, 2024
·
4 min read
Press Releases
Theralase(R) Closes Non-Brokered Private Placement
November 18, 2024
·
5 min read
Press Releases
Theralase(R) Release’s 3Q2024 Financial Statements
November 27, 2024
·
19 min read
1 of 71,931
Next
